IDRI’s expertise in a number of areas – from antigen discovery to adjuvant formulation – opens up the door to a variety of collaborations, all focused on discovery new products for infectious disease.


Antigens are substances that promote an immune response when introduced into the body. In small amounts, they are useful in the production of vaccines, as well as in developing methods for detecting disease pathogens in patients or in the blood supply. Currently, there are many global diseases for which there are no vaccines and for which improved diagnostic products are needed. Our antigen development team has experience producing antigens, typically proteins or complex sugars called “polysaccharides,” that can be used to diagnose and vaccinate against these diseases.

Our team uses many techniques to identify potential vaccine antigens. We currently possess proprietary antigens that are being used in a number of vaccine development programs.

We are interested in collaborating with others with novel antigens, as well as partnering with entities with complementary technology that can be used together with our antigens for additional vaccine and diagnostic programs.


Our adjuvant and delivery team has been developing and studying novel adjuvants for use in vaccines for many threats to human health including the flu, TB and HIV/AIDS. We have discovered new molecules based on bacterial and viral surfaces that effectively trigger key alarm systems in the body. These systems, known as Toll-like receptors (TLRs), can be safely exploited to formulate adjuvants that will generate powerful and long-lived immune responses to safe subunit vaccines. Our work in this field has generated numerous publications and interest from governments and companies that would like to develop effective vaccination strategies with few side effects.

The method of delivering the antigen-adjuvant mixture also has significant impact on vaccine potency. Some of the different delivery systems we are examining include emulsions, liposomes, naked DNA and adenoviral vectors.

We are interested in pursuing relationships with others who have novel adjuvant or delivery technologies, as well as relationships with those who can utilize our proprietary adjuvants in their product development efforts.


We are uniquely positioned to transform candidate vaccines, diagnostics and therapeutics into viable tools to control diseases of global importance. We have experience in translating late-stage research through the development pathway, and in leveraging commercial partnerships to get products on the market. Additionally, we have expertise in protein and adjuvant process development, formulation, and manufacturing, as well as in regulatory affairs and clinical development.

Our process science group develops methods for producing recombinant proteins that can be transferred to large-scale manufacturing by partners. The group also applies up-to-date technologies in formulation and product characterization.

Our adjuvant formulation group produces a variety of adjuvants for use in vaccine research by us and our partners. Our group implements and transfers adjuvant processes to our in-house cGMP production facility for manufacture of clinical Phase 1/2 material. The manufacturing group encompasses production, formulation, fill/finish and quality functions.

Our clinical development team designs and implements clinical trials in support of our global mission. Candidates are either developed by our preclinical biology group or obtained from an external source through an institutional agreement. Through our extensive network of global connections, our clinical development team is able to prepare and launch clinical trials almost anywhere in the world.

We are interested in partners with promising product candidates that fit with our technical expertise and our mission.


Our drug discovery research group focuses on identifying novel drug targets and new chemical entities as candidates to treat infectious diseases. Our current emphasis is on tuberculosis. We use innovative genetics tools to identify and validate novel drug targets in Mycobacterium tuberculosis. We also have dedicated BL3 facilities and extensive experience in the microbiology of M. tuberculosis.

When a disease target is identified from our discovery biology programs or from a collaborating laboratory, assays are developed and validated for high-throughput screening. Our robotic screening center can conduct screens based on a biochemical assay or against virulent M. tuberculosis in a BSL-3 facility. Promising hit compounds are then further tested and developed by our medicinal chemists with the aim of identifying lead compounds for preclinical testing.

We are interested in collaborating on new target identification projects, new screening assays, or new classes of potential anti-microbial compounds.

If you are interested in learning more about collaborating with IDRI in one of these areas, please contact